The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies
INTRODUCTION: The aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment. METHODS: cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first bio...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Pan African Medical Journal
2021-02-01
|
| Series: | The Pan African Medical Journal |
| Subjects: | |
| Online Access: |
https://www.panafrican-med-journal.com/content/article/38/183/pdf/183.pdf
|
| _version_ | 1828429420430360576 |
|---|---|
| author | Meryem Eddaoudi Samira Rostom Ihsane Hmamouchi Imane El Binoune Bouchra Amine Redouane Abouqal Lahsen Achemlal Fadoua Allali Imane El Bouchti Abdellah El Maghraoui Imad Ghozlani Hasna Hassikou Taoufik Harzy Linda Ichchou Ouafae Mkinsi Redouane Niamane Rachid Bahiri |
| author_facet | Meryem Eddaoudi Samira Rostom Ihsane Hmamouchi Imane El Binoune Bouchra Amine Redouane Abouqal Lahsen Achemlal Fadoua Allali Imane El Bouchti Abdellah El Maghraoui Imad Ghozlani Hasna Hassikou Taoufik Harzy Linda Ichchou Ouafae Mkinsi Redouane Niamane Rachid Bahiri |
| author_sort | Meryem Eddaoudi |
| collection | DOAJ |
| description | INTRODUCTION: The aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment. METHODS: cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first biological treatment either: Rituximab, an anti-TNF, or Tocilizumab. The determinants related to the patient and disease have been gathered. A univariate and then multivariate analysis to determine the factors associated with the choice of the first bDMARDs was realized. RESULTS: a total of 225 rheumatoid arthritis patients were included in the Moroccan registry. The mean age was 52 ± 11 years, with female predominance 88% (n = 197). The first prescribed biological treatment was Rituximab 74% (n = 166), the second one was Tocilizumab, 13.6% (n = 31) then comes the anti-TNF in 3rd position with 12.4% (n = 28). The factors associated with the choice of Rituximab as the first line bDMARDs prescribed in univariate analysis were: the insurance type, the positivity of the rheumatoid factor. In multivariate analysis, only the insurance type that remains associated with the choice of Rituximab as the first biological drugs. The Tocilizumab was associated with shorter disease duration and was more prescribed as mono-therapy compared to non Tocilizumab group. TNFi was associated with the insurance type. CONCLUSION: our study suggests that Rituximab and TNFi are associated with the type of insurance and Tocilizumab is the most prescribed biologic mono-therapy in RA patients. Further studies are needed to confirm these results. |
| first_indexed | 2024-12-10T17:33:58Z |
| format | Article |
| id | doaj.art-aa7aeabc9ef84eab9c8764249567f97e |
| institution | Directory Open Access Journal |
| issn | 1937-8688 1937-8688 |
| language | English |
| last_indexed | 2024-12-10T17:33:58Z |
| publishDate | 2021-02-01 |
| publisher | The Pan African Medical Journal |
| record_format | Article |
| series | The Pan African Medical Journal |
| spelling | doaj.art-aa7aeabc9ef84eab9c8764249567f97e2022-12-22T01:39:36ZengThe Pan African Medical JournalThe Pan African Medical Journal1937-86881937-86882021-02-013818310.11604/pamj.2021.38.183.2708127081The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapiesMeryem Eddaoudi0Samira Rostom1Ihsane Hmamouchi2Imane El Binoune3Bouchra Amine4Redouane Abouqal5Lahsen Achemlal6Fadoua Allali7Imane El Bouchti8Abdellah El Maghraoui9Imad Ghozlani10Hasna Hassikou11Taoufik Harzy12Linda Ichchou13Ouafae Mkinsi14Redouane Niamane15Rachid Bahiri16 Rheumatology Department A El Ayachi Hospital, Ibn Sina University Hospital, Rabat-Sale, Morocco Rheumatology Department A El Ayachi Hospital, Ibn Sina University Hospital, Rabat-Sale, Morocco Laboratory of Epidemiology and Clinical Research, Faculty of Medicine and Pharmacy, Rabat, Morocco Rheumatology Department A El Ayachi Hospital, Ibn Sina University Hospital, Rabat-Sale, Morocco Rheumatology Department A El Ayachi Hospital, Ibn Sina University Hospital, Rabat-Sale, Morocco Laboratory of Epidemiology and Clinical Research, Faculty of Medicine and Pharmacy, Rabat, Morocco Rheumatology Department Military Hospital Mohamed V, Ibn Sina University Hospital, Rabat, Morocco Rheumatology Department B El Ayachi Hospital, Ibn Sina University Hospital, Rabat-Salé, Morocco, Rheumatology Department Arrazi Hospital, University Hospital Mohammed VI, Marrakech, Morocco Rheumatology Medical Office, Rabat, Morocco Rheumatology Department, University Hospital, Agadir, Morocco Rheumatology Department Military Hospital, Hassan II University Hospital, Meknes, Morocco Rheumatology Department, University Hospital Hassan II, Fès, Morocco Rheumatology Department, University Hospital Mohammed VI, Oujda, Morocco Rheumatology Department, University Hospital Ibn Rochd, Casablanca, Morocco Rheumatology Department Military Hospital Avicenne, University Hospital Mohammed VI, Marrakech, Morocco Rheumatology Department A El Ayachi Hospital, Ibn Sina University Hospital, Rabat-Sale, Morocco INTRODUCTION: The aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment. METHODS: cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first biological treatment either: Rituximab, an anti-TNF, or Tocilizumab. The determinants related to the patient and disease have been gathered. A univariate and then multivariate analysis to determine the factors associated with the choice of the first bDMARDs was realized. RESULTS: a total of 225 rheumatoid arthritis patients were included in the Moroccan registry. The mean age was 52 ± 11 years, with female predominance 88% (n = 197). The first prescribed biological treatment was Rituximab 74% (n = 166), the second one was Tocilizumab, 13.6% (n = 31) then comes the anti-TNF in 3rd position with 12.4% (n = 28). The factors associated with the choice of Rituximab as the first line bDMARDs prescribed in univariate analysis were: the insurance type, the positivity of the rheumatoid factor. In multivariate analysis, only the insurance type that remains associated with the choice of Rituximab as the first biological drugs. The Tocilizumab was associated with shorter disease duration and was more prescribed as mono-therapy compared to non Tocilizumab group. TNFi was associated with the insurance type. CONCLUSION: our study suggests that Rituximab and TNFi are associated with the type of insurance and Tocilizumab is the most prescribed biologic mono-therapy in RA patients. Further studies are needed to confirm these results. https://www.panafrican-med-journal.com/content/article/38/183/pdf/183.pdf rituximabrheumatoid arthritistreatmenttnf inhibitorstocilizumab |
| spellingShingle | Meryem Eddaoudi Samira Rostom Ihsane Hmamouchi Imane El Binoune Bouchra Amine Redouane Abouqal Lahsen Achemlal Fadoua Allali Imane El Bouchti Abdellah El Maghraoui Imad Ghozlani Hasna Hassikou Taoufik Harzy Linda Ichchou Ouafae Mkinsi Redouane Niamane Rachid Bahiri The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies The Pan African Medical Journal rituximab rheumatoid arthritis treatment tnf inhibitors tocilizumab |
| title | The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies |
| title_full | The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies |
| title_fullStr | The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies |
| title_full_unstemmed | The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies |
| title_short | The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies |
| title_sort | first biological choice in patients with rheumatoid arthritis data from the moroccan register of biotherapies |
| topic | rituximab rheumatoid arthritis treatment tnf inhibitors tocilizumab |
| url |
https://www.panafrican-med-journal.com/content/article/38/183/pdf/183.pdf
|
| work_keys_str_mv | AT meryemeddaoudi thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT samirarostom thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT ihsanehmamouchi thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT imaneelbinoune thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT bouchraamine thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT redouaneabouqal thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT lahsenachemlal thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT fadouaallali thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT imaneelbouchti thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT abdellahelmaghraoui thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT imadghozlani thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT hasnahassikou thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT taoufikharzy thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT lindaichchou thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT ouafaemkinsi thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT redouaneniamane thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT rachidbahiri thefirstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT meryemeddaoudi firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT samirarostom firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT ihsanehmamouchi firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT imaneelbinoune firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT bouchraamine firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT redouaneabouqal firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT lahsenachemlal firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT fadouaallali firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT imaneelbouchti firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT abdellahelmaghraoui firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT imadghozlani firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT hasnahassikou firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT taoufikharzy firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT lindaichchou firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT ouafaemkinsi firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT redouaneniamane firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies AT rachidbahiri firstbiologicalchoiceinpatientswithrheumatoidarthritisdatafromthemoroccanregisterofbiotherapies |